Refractory granuloma faciale successfully treated with adjunct topical JAK inhibitor

Topical ruxolitinib for the treatment of granuloma faciale

“…Of note, there is a report of refractory GF successfully treated with adjunct topical tofacitinib. 5 The patient failed to adequately respond to oral dapsone, methotrexate and hydroxychloroquine, intralesional triamcinolone, and topical clobetasol; however, once tofacitinib was added to the patient’s treatment regimen, she demonstrated significant improvement. 5 No side effects were reported after the addition of topical tofacitinib.…”

“… 5 The patient failed to adequately respond to oral dapsone, methotrexate and hydroxychloroquine, intralesional triamcinolone, and topical clobetasol; however, once tofacitinib was added to the patient’s treatment regimen, she demonstrated significant improvement. 5 No side effects were reported after the addition of topical tofacitinib. 5 We did not find any reports of oral JAK inhibitors being used to treat GF.…”

“… 5 No side effects were reported after the addition of topical tofacitinib. 5 We did not find any reports of oral JAK inhibitors being used to treat GF.…”

Granuloma faciale as a diagnostic and therapeutic challenge

“…Therapeutic management of patients diagnosed with granuloma faciale is a complex issue. As yet, there are no widely accepted therapeutic recommendations for GF in the existing literature (table 5) [25,[43][44][45].…”

A Case Series of Extrafacial Granuloma Faciale

“…Granuloma faciale (GF) is an uncommon inflammatory dermatosis involving persistent reddish brown or violaceous patches, papules, nodules, or plaques. [ 1 2 3 ] Classically, it involves the face (especially, nose, forehead, and cheeks),[ 4 ] with extrafacial involvement being uncommon. [ 5 ] Lesions may demonstrate a smooth surface with superficial telangiectasia, follicular accentuation, and a peau d’orange appearance.…”